On June 21, 2022, Dermata Therapeutics, Inc. announced that Christopher J. Nardo, Ph.D., the Company's Senior Vice President of Development, was promoted to Senior Vice President, Chief Development Officer, effective July 1, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.3 USD | -1.29% | -10.16% | -74.86% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-74.86% | 1.31M | |
+16.32% | 122B | |
+19.38% | 113B | |
+18.89% | 26.49B | |
-23.45% | 19.4B | |
-19.03% | 16.24B | |
-20.44% | 15.4B | |
-46.14% | 15.15B | |
+63.80% | 14.93B | |
+4.33% | 13.52B |
- Stock Market
- Equities
- DRMA Stock
- News Dermata Therapeutics, Inc.
- Dermata Therapeutics, Inc Promotes Christopher J. Nardo as Senior Vice President, Chief Development Officer, Effective July 1, 2022